Healius stock heads toward October 22 AGM as losses narrow

Published on 10/08/2026 at 06:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Healius stock was trading at AUD 0.40 on October 8, 2026, while the company prepares for its October 22 AGM. FY2026 EBIT rose to AUD 30.2 million.

Healius, AU0000033359, Illustration mit AI erstellt.

Healius Limited (ISIN AU0000033359) had a market capitalization of AUD 290.5 million on October 8, 2026, as the company prepares for its 2026 annual general meeting. According to TipRanks, the meeting is scheduled for October 22, 2026, at 11:00 a.m. Sydney time.

AGM puts capital allocation ahead

The AGM comes after Healius agreed to sell Agilex Biolabs to Novotech for an enterprise value of AUD 160 million. BBRW reported that completion is targeted for the second half of fiscal year 2027, subject to regulatory approvals.

The transaction gives management a clear capital-allocation question for the meeting: whether proceeds should support debt reduction, investment in pathology or a return of capital. Healius has said its strategy is narrowing toward pathology after the disposal of non-core assets.

FY2026 EBIT more than doubled

According to the Yahoo Finance transcript of the FY2026 earnings call, underlying revenue increased 2.1 percent to AUD 1.37 billion, while underlying EBIT rose from AUD 17.1 million to AUD 30.2 million. The result is a quantified improvement, but the group still reported a statutory loss for the year.

The same transcript showed pathology revenue of AUD 1.33 billion and pathology EBITDA of AUD 247.9 million in FY2026. Agilex contributed AUD 43.6 million of revenue and AUD 6.4 million of EBIT before its planned sale, making the disposal financially material even though the pathology division remains the core operating business.

Analyst targets remain above market

Analyst expectations provide a second benchmark for the AGM discussion. Simply Wall St reported on August 21, 2026, that the average target from 10 analysts had risen to AUD 0.55 from AUD 0.50. The page said the new target was 20 percent above the then-prevailing close of AUD 0.46.

TipRanks listed the most recent rating as Hold with an AUD 0.50 price target. The gap between those targets and the current quotation leaves capital allocation, regulatory approval and pathology margins as the central issues for shareholders.

Healius stock trades at AUD 0.40

Healius stock was last at AUD 0.40 on ASX on October 8, 2026, at 3:11 p.m. Sydney time, down 2.44 percent from AUD 0.41. The same session showed a 52-week range of AUD 0.30 to AUD 1.07 and volume of 737,102 shares.